BTK inhibitors are moving from relapsed treatment to frontline therapy for Mantle Cell Lymphoma (MCL). A key question is whether patients who relapse after a fixed-duration BTK inhibitor can be successfully treated with the same drug again. In the past, failing a BTK inhibitor left patients with very limited options, so proving that “rechallenge” works is important before making these regimens standard frontline care.
Several major trials are shaping this approach. The TRIANGLE Phase 3 trial showed that adding ibrutinib to chemotherapy and continuing it for two years improved four-year failure-free survival compared with transplant alone. The TrAVeRse trial is testing a chemotherapy-free combination of acalabrutinib, venetoclax, and rituximab, using minimal residual disease (MRD) testing to guide when treatment can stop. The BOVen study is focusing on high-risk patients with TP53 mutations and has shown deep molecular remissions, offering hope for a group once considered very difficult to treat.
Treatment decisions are now more personalized rather than based only on age. Doctors aim for deep, long-lasting remissions while balancing side effects. Although outcomes for patients with TP53 mutations are improving, patients with blastoid or pleomorphic disease and certain genetic mutations, such as NOTCH and KMT2A, still need better treatment options.